Usefulness of Nutraceuticals (Armolipid Plus) Versus Ezetimibe and Combination in Statin-Intolerant Patients with Dyslipidemia with Coronary Heart Disease

American Journal of Cardiology

Volumn 116, Issue 12, 2015, Pages 1798-1801

  Marazzi, Giuseppe ^a   Pelliccia, Francesco ^b   Campolongo, Giuseppe ^a   Quattrino, Silvia ^a   Cacciotti, Luca ^c   Volterrani, Maurizio ^a   Gaudio, Carlo ^b   Rosano, Giuseppe ^a  

^a IRCCS SAN RAFFAELE PISANA   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c Madre Giuseppina Vannini Hospital   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ARMOLIPID PLUS; ASPARTATE AMINOTRANSFERASE; ASTAXANTHIN; BERBERINE; CHOLESTIN; CREATINE KINASE; EZETIMIBE; FOLIC ACID; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NUTRACEUTICAL; POLICOSANOL; TRIACYLGLYCEROL; UBIDECARENONE; UNCLASSIFIED DRUG; CHOLESTEROL;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CHOLESTEROL BLOOD LEVEL; CLINICAL PRACTICE; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TOLERABILITY; DYSLIPIDEMIA; FEMALE; FOLLOW UP; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; PARALLEL DESIGN; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SINGLE BLIND PROCEDURE; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL; BLOOD; COMPLICATION; CORONARY ARTERY DISEASE; DIET SUPPLEMENTATION; DRUG COMBINATION; DYSLIPIDEMIAS; MIDDLE AGED; TREATMENT OUTCOME;

CHOLESTEROL; CORONARY ARTERY DISEASE; DIETARY SUPPLEMENTS; DRUG THERAPY, COMBINATION; DYSLIPIDEMIAS; EZETIMIBE; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; SINGLE-BLIND METHOD; TREATMENT OUTCOME;

EID: 84951842352     PISSN: 00029149     EISSN: 18791913     Source Type: Journal    
DOI: 10.1016/j.amjcard.2015.09.023     Document Type: Article

References (25)

1. E.K. Kalra Nutraceutical-definition and introduction AAPS Pharm Sci 5 2003 E25
2. A. Endo The origin of the statins. 2004 Atheroscler Suppl 5 2004 125 130
3. S.C. Halbert, B. French, R.Y. Gordon, J.T. Farrar, K. Schmitz, P.B. Morris, P.D. Thompson, D.J. Rader, and D.J. Becker Tolerability of red yeast rice (2,400 mg twice daily) versus pravastatin (20 mg twice daily) in patients with previous statin intolerance Am J Cardiol 105 2010 198 204
4. M. Karl, M. Rubenstein, C. Rudnick, and J. Brejda A multicenter study of nutraceutical drinks for cholesterol (evaluating effectiveness and tolerability) J Clin Lipidol 6 2012 150 158
5. A.F. Cicero, G. Derosa, A. Parini, P. Maffioli, S. D'Addato, A. Reggi, M. Giovannini, and C. Borghi Red yeast rice improves lipid pattern, high-sensitivity C-reactive protein, and vascular remodeling parameters in moderately hypercholesterolemic Italian subjects Nutr Res 33 2013 622 628
6. D.J. Becker, R.Y. Gordon, S.C. Halbert, B. French, P.B. Morris, and D.J. Rader Red yeast rice for dyslipidemia in statin-intolerant patients: a randomized trial Ann Intern Med 150 2009 830 839
7. M.P. Bogsrud, L. Ose, G. Langslet, I. Ottestad, E.C. Strøm, T.A. Hagve, and K. Retterstøl HypoCol (red yeast rice) lowers plasma cholesterol- a randomized placebo controlled study Scand Cardiovasc J 44 2010 197 200
8. F. Affuso, V. Mercurio, V. Fazio, and S. Fazio Cardiovascular and metabolic effects of Berberine World J Cardiol 2 2010 71 77
9. A.F. Cicero, L.C. Rovati, and I. Setnikar Eulipidemic effects of berberine administered alone or in combination with other natural cholesterol-lowering agents. A single-blind clinical investigation Arzneimittelforschung 57 2007 26 30
10. M. Ruscica, M. Gomaraschi, G. Mombelli, C. Macchi, R. Bosisio, F. Pazzucconi, C. Pavanello, L. Calabresi, A. Arnoldi, C.R. Sirtori, and P. Magni Nutraceutical approach to moderate cardiometabolic risk: results of a randomized, double-blind and crossover study with Armolipid Plus J Clin Lipidol 8 2014 61 68
11. E. Barrat, Y. Zaïr, N. Ogier, B. Housez, C. Vergara, C. Maudet, J.F. Lescuyer, J.M. Bard, Y.A. Carpentier, M. Cazaubiel, and S.L. Peltier A combined natural supplement lowers LDL cholesterol in subjects with moderate untreated hypercholesterolemia: a randomized placebo-controlled trial Int J Food Sci Nutr 64 2013 882 889
12. L. Pisciotta, A. Bellocchio, and S. Bertolini Nutraceutical pill containing berberine versus ezetimibe on plasma lipid pattern in hypercholesterolemic subjects and its addictive effect in patients with familial hypercholesterolemia on stable cholesterol-lowering treatment Lipids Health Dis 11 2012 123
13. G. Marazzi, L. Cacciotti, F. Pelliccia, L. Iaia, M. Volterrani, G. Caminiti, B. Sposato, R. Massaro, F. Grieco, and G. Rosano Long-term effects of nutraceuticals (berberine, red yeast rice, policosanol) in elderly hypercholesterolemic patients Adv Ther 28 2011 1105 1113
14. A.S. Levey, J. Coresh, T. Greene, L.A. Stevens, Y.L. Zhang, S. Hendriksen, J.W. Kusek, F. Van Lente Chronic Kidney Disease Epidemiology Collaboration Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate Ann Intern Med 45 2006 247 254
15. A. Endo Chemistry, biochemistry, and pharmacology of HMG-CoA reductase inhibitors Klin Wochenschr 66 1988 421 427
16. R.Y. Man, E.G. Lynn, F. Cheung, P.S. Tsang O K Cholestin inhibits cholesterol synthesis and secretion in hepatic cells (HepG2) Mol Cell Biochem 233 2002 153 158
17. R. Menendez, A.M. Amor, I. Rodeiro, R.M. González, P.C. González, J.L. Alfonso, and R. Más Policosanol modulates HMG-CoA reductase activity in cultured fibroblasts Arch Med Res 32 2001 8 12
18. J. Cameron, T. Ranheim, M.A. Kulseth, T.P. Leren, and K.E. Berge Berberine decreases PCSK9 expression in HepG2 cells Atherosclerosis 201 2008 266 273
19. W. Kong, J. Wei, P. Abidi, M. Lin, S. Inaba, C. Li, Y. Wang, Z. Wang, S. Si, H. Pan, S. Wang, J. Wu, Y. Wang, Z. Li, J. Liu, and J.D. Jiang Berberine is a novel cholesterol-lowering drug working through a unique mechanism distinct from statins Nat Med 10 2004 1344 1351
20. A. Pandor, R.M. Ara, I. Tumur, A.J. Wilkinson, S. Paisley, A. Duenas, P.N. Durrington, and J. Chilcott Ezetimibe monotherapy for cholesterol lowering in 2722 people: systematic review and meta-analysis of randomized controlled trials J Intern Med 265 2009 568 580
21. F. Affuso, A. Ruvolo, F. Micillo, L. Saccà, and S. Fazio Effects of a nutraceutical combination (berberine, red yeast rice and policosanols) on lipid levels and endothelial function randomized, double-blind, placebo-controlled study Nutr Metab Cardiovasc Dis 20 2010 656 661
22. A.F. Cicero, A. Ferroni, and S. Ertek Tolerability and safety of commonly used dietary supplements and nutraceuticals with lipid-lowering effects Expert Opin Drug Saf 11 2012 753 766
23. F. Affuso, V. Mercurio, A. Ruvolo, C. Pirozzi, F. Micillo, G. Carlomagno, F. Grieco, and S. Fazio A nutraceutical combination improves insulin sensitivity in patients with metabolic syndrome World J Cardiol 4 2012 77 83
24. R. Solà, R.M. Valls, J. Puzo, J.R. Calabuig, A. Brea, A. Pedret, D. Moriña, J. Villar, J. Millán, and A. Anguera Effects of poly-bioactive compounds on lipid profile and body weight in a moderately hypercholesterolemic population with low cardiovascular disease risk: a multicenter randomized trial PLoS One 9 2014 e101978
25. M. Banach, M. Rizzo, P.P. Toth, M. Farnier, M.H. Davidson, K. Al-Rasadi, W.S. Aronow, V. Athyros, D.M. Djuric, M.V. Ezhov, R.S. Greenfield, G.K. Hovingh, K. Kostner, C. Serban, D. Lighezan, Z. Fras, P.M. Moriarty, P. Muntner, A. Goudev, R. Ceska, S.J. Nicholls, M. Broncel, D. Nikolic, D. Pella, R. Puri, J. Rysz, N.D. Wong, L. Bajnok, S.R. Jones, K.K. Ray, and D.P. Mikhailidis Statin intolerance- an attempt at a unified definition. Position paper from an International Lipid Expert Panel Arch Med Sci 11 2015 1 23